Crizotinib/gefitinibDevelopment of resistance: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2017年 / 1676卷 / 1期

关键词：

D O I：

10.1007/s40278-017-38095-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：107 / 107

相关论文

共 50 条

[21] Alectinib/crizotinib/lorlatinibDrug resistance: case report
Reactions Weekly, 2020, 1798 (1) : 22 - 22
[22] Docetaxel/gefitinibDevelopment of resistance in lung adenocarcinoma and infusion reaction: case report
Reactions Weekly, 2016, 1583 (1) : 422 - 422
[23] Afatinib/gefitinibDevelopment of resistance to gefitinib and afatinib in lung adenocarcinoma: case report
Reactions Weekly, 2019, 1771 (1) : 21 - 21
[24] GefitinibDevelopment of resistance in metastatic non small cell lung cancer: case report
Reactions Weekly, 2017, 1670 (1) : 135 - 135
[25] GefitinibDevelopment of gefitinib resistance in lung adenocarcinoma leading to treatment failure: case report
Reactions Weekly, 2018, 1714 (1) : 201 - 201
[26] CrizotinibALK mutations with acquired resistance to crizotinib: case report
Reactions Weekly, 2015, 1551 (1) : 89 - 89
[27] Crizotinib/selpercatinibDrug resistance and lack of response: case report
Reactions Weekly, 2022, 1918 (1) : 165 - 165
[28] Alectinib/crizotinib/lorlatinibAcquired drug resistance: case report
Reactions Weekly, 2024, 2026 (1) : 24 - 24
[29] Afatinib/crizotinib/erlotinibAcquired EGFR resistance: case report
Reactions Weekly, 2016, 1603 (1) : 15 - 15
[30] Brigatinib/crizotinib/lorlatinibAcquired drug resistance: case report
Reactions Weekly, 2023, 1963 (1) : 135 - 135

← 1 2 3 4 5 →